AMB-05X
Sponsors
Ammax Bio Inc., AmMax Bio, Inc., M.D. Anderson Cancer Center
Conditions
Colorectal CancerIPFPVNS - Pigmented Villonodular SynovitisPigmented Villonodular SynovitisPigmented Villonodular Synovitis (PVNS)TGCTTenosynovial Giant Cell Tumor
Phase 2
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
CompletedNCT04731675
Start: 2021-05-25End: 2022-05-05Updated: 2024-06-27
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
TerminatedNCT04938180
Start: 2021-09-16End: 2022-05-17Updated: 2024-05-24
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
WithdrawnNCT05349760
Start: 2023-03-31End: 2025-06-30Updated: 2023-01-19
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
CompletedNCT05349643
Start: 2023-01-26End: 2024-06-03Updated: 2024-07-05
A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects with Tenosynovial Giant Cell Tumor
CompletedCTIS2023-507328-22-00
Start: 2022-12-20End: 2024-04-26Target: 20Updated: 2024-01-26
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
RecruitingNCT06617858
Start: 2024-12-04End: 2028-02-01Target: 15Updated: 2026-08-25